Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,063.85 +45.46 (+0.91%) Dow
38,226.71 +323.42 (+0.85%) Nasdaq
15,831.89 +226.41 (+1.45%) Bitcoin USD
59,084.25 +1,371.31 (+2.38%) CMC Crypto 200
1,275.54 +4.79 (+0.38%)
Moderna, Inc. (0QF.MU)
| Previous close | 104.52 |
| Open | 104.52 |
| Bid | 116.22 x 0 |
| Ask | 116.52 x 0 |
| Day's range | 104.84 - 115.80 |
| 52-week range | 64.86 - 132.54 |
| Volume | |
| Avg. volume | 25 |
| Market cap | 44.338B |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- ACCESSWIRE
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222 Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against ...
- PR Newswire
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need. This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage
- Business Wire
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
RAHWAY, N.J. & CAMBRIDGE, Mass., December 11, 2023--Merck and Moderna Initiate INTerpath-002 Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA for Certain Types of Resected NSCLC
